May 13th 2024
The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Gene therapy helps patient with retinitis pigmentosa achieve partial vision
May 26th 2021An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.
Clinical results analyze dexamethasone implant effect on macular thickness
May 5th 2021Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
DMO study shows robust efficacy of intravitreal dexamethasone implant
April 16th 2021In a real-world study of patients with treatment-naïve and previously treated diabetic macular oedema, injection of intravitreal dexamethasone 0.7-mg implant provided effective disease control with initial and repeat injections, regardless of reinjection interval.
The quest for topical treatments for the posterior segment
April 14th 2021Topical eye drop treatments for the posterior segment would offer easier, less invasive options than those currently available. This would reduce the burden on both patients and their caregivers, increasing adherence and improving outcomes.
Study targets strategies for CI-DMO
March 22nd 2021In the DRCR Retina Network Protocol V, which studied management strategies for eyes with centre-involving DMO and good visual acuity, the majority of eyes randomly assigned to initial observation completed the 2-year study without needing anti-VEGF therapy for vision loss and nearly one-third had spontaneous resolution of DMO.
Brolucizumab for neovascular AMD: Safety guidance and clinician perspectives
March 3rd 2021Although the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.
Learning the basics of age-related macular degeneration
February 3rd 2021Ian C. Han, MD, assistant professor in the Department of Ophthalmology and Visual Sciences, Institute for Vision Research, University of Iowa Hospital and Clinics, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.
Investigators explore pathogenic cytokines as biomarkers for DMO
January 27th 2021Results of a study analysing cytokine levels in the aqueous humour and serum of patients with nonproliferative diabetic retinopathy with and without diabetic macular oedema support further research investigating transforming growth factor-β-induced Gene Human Clone 30 (BIGH3) as a potential biomarker for DMO.
Risks and management of diabetic retinopathy in paediatric patients
January 13th 2021Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.
Roche’s DME candidate hits mark in 2 global Phase 3 studies
January 6th 2021Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.